NEW YORK (GenomeWeb) – Bio-Rad Laboratories has received CE-IVD marking on a droplet digital PCR assay to detect BCR-ABL gene fusions. The test can be used to monitor response to treatment in patients with chronic myeloid leukemia and is Bio-Rad's first clinical ddPCR assay to receive a CE mark.

To read the full story....

Register for Free.

Already have a GenomeWeb or 360Dx account?
Login Now.